SCHEMBL4496147

SCHEMBL4496147

O=C1Nc2cc(F)ccc2C1=C(Nc1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.49
TGM2 P21980 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PDGFRB P09619 3/20 0.39
KCNK3 O14649 2/20 0.39
KCNK9 Q9NPC2 1/20 0.39
HTT P42858 1/20 0.38
FLT3 P36888 2/20 0.38
KIT P10721 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 2/20 0.38
AURKA O14965 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496144 1.00 BACE1 (0.49) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL4502433 0.89 BACE1 (0.45) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL4502439 0.89 BACE1 (0.45) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL226114 0.88 BACE1 (0.47) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL226113 0.88 BACE1 (0.47) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL4504086 0.88 BACE1 (0.44) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL4501618 0.87 BACE1 (0.43) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL4501619 0.87 BACE1 (0.43) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL4482182 0.87 BACE1 (0.50) BACE1TGM2SMN1; SMN2TP53MAPT
SCHEMBL4482176 0.87 BACE1 (0.50) BACE1TGM2SMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR BACE1 1615/4885TGM2 4379/4885SMN1; SMN2 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.